ArQule Reports Third Quarter 2015 Financial Results
November 04, 2015 07:00 ET
|
ArQule, Inc.
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., Nov. 04, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the third quarter of...
ArQule to Present Data on Tivantinib, ARQ 087, ARQ 092, and ARQ 751 at AACR-NCI-EORTC Conference
October 27, 2015 07:30 ET
|
ArQule, Inc.
Single-agent and combination pre-clinical and clinical data supportive of on-going clinical trials BURLINGTON, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced...
ArQule to Report Third Quarter 2015 Financial Results on November 4, 2015
October 21, 2015 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Oct. 21, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it will report financial results for the third quarter 2015 before the market opens on Wednesday,...
ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 and Next Generation AKT Inhibitor ARQ 751 in Oncology
October 15, 2015 16:00 ET
|
ArQule, Inc.
Pre-Clinical Data Supports the Use of AKT1 and PI3K Mutations as Biomarkers for the Company’s AKT Inhibitors BURLINGTON, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today...
ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference
September 28, 2015 07:30 ET
|
ArQule, Inc.
Preliminary Results of the Phase 1b Expansion Cohort Show Four Partial Responses in Targeted Patient Populations BURLINGTON, Mass., Sept. 28, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc....
ArQule to Present at Leerink Partners 4th Annual Rare Disease Roundtable on September 30, 2015
September 25, 2015 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Sept. 25, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Dr. Brian Schwartz, Head of Research and Development and Chief Medical Officer, will present...
ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference
September 08, 2015 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Sept. 08, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that additional analyses of plasma biomarkers support the prognostic and predictive role of MET...
ArQule Reports Second Quarter 2015 Financial Results
August 05, 2015 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., Aug. 05, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the second quarter of 2015. For the quarter ended June 30, 2015,...